Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
Loading IDRA News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.24%||67.26||1.0%||$568.09m|
|REGN||Regeneron Pharmaceuticals, Inc.||3.03%||394.14||2.1%||$385.16m|
|VRTX||Vertex Pharmaceuticals Incorporated||20.45%||108.01||2.0%||$218.70m|
|KITE||Kite Pharma, Inc.||-0.13%||78.51||17.5%||$216.08m|
|ALXN||Alexion Pharmaceuticals, Inc.||1.85%||120.72||1.6%||$208.60m|
|ESPR||Esperion Therapeutics, Inc.||-2.44%||34.79||17.7%||$146.82m|
|CLVS||Clovis Oncology, Inc.||-3.98%||64.39||17.2%||$135.52m|
|AUPH||Aurinia Pharmaceuticals Inc.||1.96%||7.30||8.0%||$134.79m|
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. Idera Pharmaceuticals was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.